Recent Updates
Recently added Catalysts
TWST Positive Sentiment

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

Key Takeaway: Twist Bioscience Corporation has entered into a partnership with Lilly TuneLab, an AI/ML drug discovery platform developed by Eli Lilly. This collaboration will allow Twist to provide antibody characterization data services, including the AbLab model, to enhance the drug discovery process. The partnership aims to foster innovation in the biotech sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with Eli Lilly enhances drug discovery capabilities.
  • Twist Bioscience provides valuable antibody characterization data.
  • The partnership aims to accelerate biotech innovation.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan

Frequently Asked Questions

What is the purpose of the Twist and Lilly partnership?

The partnership aims to enhance antibody drug discovery using AI/ML technology.

What services does Twist provide to Lilly TuneLab?

Twist provides antibody characterization data services, including the AbLab model.

Who created the Lilly TuneLab platform?

Lilly TuneLab was created by Eli Lilly and Company.

What is the goal of Lilly TuneLab?

The goal is to accelerate biotech innovation through collaborative drug discovery.

Last updated: Sep 16, 2026